CJ Bailey, RC Turner - New England Journal of Medicine, 1996 - content.nejm.org Metformin (dimethylbiguanide) is an orally administered drug used to lower blood
glucose concentrations in patients with non-insulin-dependent diabetes mellitus
(NIDDM). 1 It improves insulin sensitivity and thus decreases the insulin ... Cited by 714 - Related articles - BL Direct - All 5 versions
M Stumvoll, N Nurjhan, G Perriello, G Dailey, … - New England Journal of Medicine, 1995 - content.nejm.org Results Metformin treatment decreased the mean (±SD) glycosylated hemoglobin
value from 13.2±2.2 percent to 10.5±1.6 percent (P<0.001) and reduced fasting
plasma glucose concentrations from 220±41 to 155±28 mg per deciliter ... Cited by 461 - Related articles - All 6 versions
- ►karolinskauniversitetssjukhuset.se [PDF] SR Salpeter, E Greyber, GA Pasternak, EE … - Archives of Internal Medicine, 2003 - archinte.highwire.org Methods A comprehensive search was performed to identify all comparative trials
or observational cohort studies published between January 1, 1959, and March 31,
2002, that evaluated metformin therapy, alone or in combination with other ... Cited by 320 - Related articles - BL Direct - All 16 versions
J Rachman, BA Barrow, JC Levy, RC Turner - Diabetologia, 1997 - Springer Non-insulin-dependent diabetes mellitus (NIDDM) is characterised by an increase
in basal glucose con- centrations, upon which are superimposed exagger- ated
postprandial glucose excursions, induced by a combination of beta-cell ... Cited by 173 - Related articles - BL Direct - All 4 versions
- ►endojournals.org LC Morin-Papunen, I Vauhkonen, RM … - Journal of Clinical Endocrinology & Metabolism, 2000 - Endocrine Soc Metformin, a biguanide antihyperglycemic drug, has been shown to improve ovarian
function and glucose metabolism in women with polycystic ovary syndrome (PCOS),
but results concerning its effects on insulin sensitivity are ... Cited by 165 - Related articles - BL Direct - All 4 versions
K Cusi, A Consoli, RA DeFronzo - Journal of Clinical Endocrinology & Metabolism, 1996 - Endocrine Soc Page 1. Journal of Clinical Endocrinology and Metabolism Copyright 0 1996
by The Endocrine Society Vol. 81, No. 11 Prrntrd m USA ... Cited by 150 - Related articles - BL Direct - All 5 versions
H Yki-Järvinen - Annals of Medicine, 2005 - informahealthcare.com Insulin resistance in humans is not always accompanied by obesity, since severe
insulin resistance also characterizes patients lacking subcutaneous fat such as
those with HAART‐ (highly‐active antiretroviral therapy)‐associated ... Cited by 145 - Related articles - BL Direct - All 10 versions
JE Gerich - Archives of Internal Medicine, 2003 - archinte.highwire.org It is well established that strict glycemic control (hemoglobin A 1c <7.0%) can
prevent the microvascular complications of diabetes mellitus. Recent studies
indicate that elevated plasma glucose concentrations are an independent and ... Cited by 134 - Related articles - BL Direct - All 5 versions
D Giugliano, A Quatraro, G Consoli, A Minei, A … - European journal of clinical pharmacology, 1993 - Springer Summary, The efficacy and safety of metformin in the treatment of obese,
non-insulin-dependent, diabetic sub- jects poorly controlled by insulin after
secondary failure to respond to sulphonylureas has been investigated. Fifty ... Cited by 123 - Related articles - BL Direct - All 3 versions
HCS Howlett, CJ Bailey - Drug safety, 1999 - ingentaconnect.com Abstract Metformin has been used for over 40 years as an effective
glucose-lowering agent in type 2 (noninsulin-dependent) diabetes mellitus.
Typically it reduces basal and postprandial hyperglycaemia by about 25% in ... Cited by 116 - Related articles - BL Direct - All 4 versions
